# Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

> **NCT00628433** · PHASE1,PHASE2 · COMPLETED · sponsor: **Harbor Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** HE3286

## Key facts

- **NCT ID:** NCT00628433
- **Lead sponsor:** Harbor Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2011-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628433, "Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00628433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*